Experimental medicines to treat patients with advanced tumors or lung cancer that have not responded to standard treatment

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Experimental treatment with Methoxyamine, Cisplatin, and Pemetrexed Disodium for advanced tumors or lung cancer"
18 to 100 years old
Healthy Volunteers:
lung cancer, lung, cancer, ovary, ovarian cancer, tumor, peritoneum, peritoneal cancer, mesothelioma
Drug study, Phase I/II
This study looks at the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with tumors or lung cancer that have spread to other places in the body and usually cannot be cured or controlled with standard treatment, or lung cancer that does not respond to pemetrexed disodium and cisplatin or carboplatin. Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for tumors or lung cancer.
This study requires

Contact for more information

Who can participate

Inclusion Criteria:

  • Arm A dose escalation: patients with histologically or cytologically proven advanced solid tumors for which standard treatments are not available, or for whom the current dose level of cisplatin in combination with pemetrexed is appropriate; =< 2 prior cytotoxic chemotherapy regimen

  • Arm A dose level 4 (75 mg/m^2 cisplatin): patients with histologically proven chemotherapy-naive advanced unresectable solid tumors for which pemetrexed combined with cisplatin is an indicated regimen (malignant mesothelioma, non-small cell lung cancer, ovarian cancer and thymoma)

  • Arm A 14-patients expansion cohort: patients with histologically or cytologically proven chemotherapy naive unresectable malignant pleural or peritoneal mesothelioma

  • Arm B (first stage of phase II of TRC102 and pemetrexed): patients with malignant pleural or peritoneal mesothelioma who had progressed while being treated with or had recurred within 6 months of being treated with pemetrexed and cisplatin or carboplatin frontline

  • Prior pemetrexed is allowed except Arm A dose level 4 (cisplatin 75 mg/m^2)

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 -1 (Karnofsky >= 70%)

  • Life expectancy of greater than 3 months

  • Absolute neutrophil count >= 1,500/uL

  • Platelets >= 100,000/uL

  • Hemoglobin >= 10.0 g/dl

  • Prothrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)

  • Total bilirubin < 1.5 x ULN

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN or =< 5 x ULN if metastatic disease involves liver

  • Serum creatinine == 60 ml/min/1.73 m^2 (Cockcroft-Gault method) for patients receiving combination of cisplatin and pemetrexed and >= 45 ml/min/1.73 m^2 for patients receiving pemetrexed; 24 hour urine for creatinine clearance is acceptable if the calculated creatinine clearance is insufficient

  • For patients enrolled in arm A dose level 4, arm A 14-patients expansion cohort, and arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable disease

  • Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed

  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of the study drugs; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of TRC102, pemetrexed and cisplatin administration

  • Non-childbearing potential is defined as (by other than medical reasons): >= 45 years of age and has not had menses for >= 2 years, amenorrheic for < 2 years without hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation, or post hysterectomy, oophorectomy or tubal ligation; documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound; tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit though 4 months after the last dose of study drugs

  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have had targeted therapy will be required to wait 2 weeks due to short half-life of the drugs; treatment with bisphosphonates is permitted

  • Patients who are receiving any other investigational agents

  • Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial; patients with treated brain metastases, whose brain metastatic disease has remained stable for greater than or equal to 4 weeks without requiring steroid and anti-seizure medications are eligible to participate

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatin

  • No studies have been performed to assess potential metabolic and transport interactions of TRC102; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; the case report form must capture the concurrent use of all other drugs, over-the-counter medications, or alternative therapies

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102

  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

  • Patients with known disorders associated with hemolysis

  • Patients with thromboembolic disease and on anticoagulation

  • Patients with a prior cumulative cisplatin dose > 300 mg/m^2

Study duration and period
Contact for more information
Recruitment period
From Jan. 28, 2016
UC Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Corinne Turrell
Research Topic
  • Advanced Malignant Solid Neoplasm
  • Advanced Peritoneal Malignant Mesothelioma
  • Advanced Pleural Malignant Mesothelioma
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Peritoneal Malignant Mesothelioma
  • Recurrent Pleural Malignant Mesothelioma
  • Stage III Non-Small Cell Lung Cancer
  • Stage III Ovarian Cancer
  • Stage III Pleural Mesothelioma
  • Stage IIIA Non-Small Cell Lung Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIB Non-Small Cell Lung Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Stage IV Ovarian Cancer
  • Stage IV Pleural Mesothelioma
  • Thymoma
  • Unresectable Solid Neoplasm

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview